CryoLife, Inc. Expected to Earn Q3 2018 Earnings of $0.02 Per Share (CRY)
CryoLife, Inc. (NYSE:CRY) – Equities researchers at First Analysis issued their Q3 2018 earnings per share estimates for shares of CryoLife in a research note issued to investors on Tuesday. First Analysis analyst anticipates that the medical equipment provider will post earnings per share of $0.02 for the quarter.
CryoLife (NYSE:CRY) last posted its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.08. CryoLife had a net margin of 5.28% and a return on equity of 6.43%. The firm had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.60 million. During the same period in the previous year, the firm posted $0.13 EPS. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year.
Shares of CryoLife (NYSE:CRY) opened at $19.20 on Friday. CryoLife has a 1-year low of $14.02 and a 1-year high of $24.00. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29. The firm has a market cap of $642.39, a P/E ratio of 46.83 and a beta of 0.82.
In other news, CEO James P. Mackin sold 125,000 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $22.01, for a total value of $2,751,250.00. Following the sale, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at approximately $8,768,761.99. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP David C. Gale sold 20,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $19.63, for a total transaction of $392,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 229,240 shares of company stock worth $4,888,065. Insiders own 6.00% of the company’s stock.
Large investors have recently bought and sold shares of the company. State of Alaska Department of Revenue boosted its stake in shares of CryoLife by 80.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 2,407 shares during the last quarter. First Mercantile Trust Co. boosted its stake in shares of CryoLife by 5.6% in the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock valued at $109,000 after purchasing an additional 291 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of CryoLife by 3.7% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 6,380 shares of the medical equipment provider’s stock valued at $127,000 after purchasing an additional 230 shares during the last quarter. Creative Planning boosted its stake in shares of CryoLife by 3.0% in the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after purchasing an additional 200 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of CryoLife by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 6,937 shares of the medical equipment provider’s stock valued at $138,000 after acquiring an additional 1,041 shares during the period. 70.34% of the stock is currently owned by institutional investors.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.